Yellow Fever Vaccination: Contraindications and Management in Immunocompromised Patients

Mechanism of Vaccine‑Derived Disease

The live‑attenuated yellow fever vaccine normally produces a brief, low‑level viremia that resolves as neutralizing antibodies appear within 4–7 days in immunocompetent recipients. [@3]
In immunocompromised individuals, inadequate immune surveillance permits uncontrolled replication of the vaccine virus, which can progress to disseminated infection and severe adverse events such as neurotropic disease (YEL‑AND) and viscerotropic disease (YEL‑AVD). [@2]

The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) consider yellow fever vaccination contraindicated in all immunocompromised patients because the live‑attenuated virus can cause severe, potentially fatal vaccine‑associated disease through uncontrolled replication. [@1][@2]

Persons with any immune‑deficiency disease—including symptomatic HIV infection, leukemia, lymphoma, or generalized malignancy—should not receive the yellow fever vaccine. [@1]

Immunosuppressive Agent	Recommended Vaccination Status
High‑dose systemic corticosteroids (≥2 mg/kg/day or ≥20 mg/day prednisone equivalent for ≥2 weeks)	Contraindicated [@2]
Alkylating agents (e.g., cyclophosphamide)	Contraindicated [@2]
Antimetabolites (e.g., azathioprine, 6‑mercaptopurine)	Contraindicated [@1]
TNF‑α inhibitors (etanercept, infliximab, adalimumab)	Contraindicated [@5]
IL‑1 blocker (anakinra)	Contraindicated [@2]
Other monoclonal antibodies targeting immune cells	Contraindicated [@2]

Solid‑organ and hematopoietic stem‑cell transplant recipients within 2 years of transplantation are considered immunosuppressed and should not be vaccinated. [@2]
Recipients beyond 2 years who remain on immunosuppressive therapy are also contraindicated. [@2]

A Swiss cohort of 15 immunosuppressed travelers receiving low‑dose methotrexate (≤20 mg/week) demonstrated adequate serologic response without serious adverse reactions after yellow fever vaccination; however, these results are limited to minimally immunosuppressed patients and should not be extrapolated to broader immunocompromised populations. [@5][@6]

Assess travel necessity – if travel can be postponed until immune function improves, vaccination should be avoided. [@2]
If travel is unavoidable, issue a medical waiver letter on official health‑department letterhead to satisfy International Certificate of Vaccination requirements. [@1][@2]
Emphasize mosquito‑bite prevention (DEET‑containing repellents, permethrin‑treated clothing, air‑conditioned or screened lodging). [@2]
Never vaccinate solely to meet administrative travel requirements when a medical contraindication exists. [@1]

Immunosuppressive Agent(s)	Recommended Waiting Period Before Vaccination
Anti‑TNF agents (infliximab, adalimumab, golimumab, certolizumab)	≥ 3 months [@5]
Thiopurines (azathioprine, 6‑mercaptopurine)	≥ 3 months [@5]
High‑dose corticosteroids, methotrexate, tofacitinib	≥ 1 month [@6]
Vedolizumab	3–4 months [@5]

The 2020 EULAR recommendations for autoimmune inflammatory rheumatic diseases state that yellow fever vaccination “should be generally avoided” rather than being an absolute contraindication, reflecting limited experience with inadvertent vaccination in this specific patient group. [@7][@3]

The absence of immediate adverse events does not guarantee safety; vaccine‑associated disease can manifest days after vaccination as viremia progresses. [@3]
Decisions should not be driven by patient insistence or travel paperwork alone, because the risk of fatal vaccine‑derived disease outweighs administrative convenience. [@1][@2]